Girdin (GIV)

**Girdin** is an actin-binding, multi-domain cytoskeletal-associated protein encoded by the CCDC88A gene in humans[3]. It is a large, predominantly alpha-helical, coiled-coil protein found ubiquitously, especially at the leading edge of migrating cells and in the cytoplasm of epithelial and neuronal cells[2]. Girdin acts as a hub for signal transduction, modulating the interplay between Akt kinase signaling, trimeric G protein pathways, and actin cytoskeleton remodeling, and is essential for directional cell migration, polarization, and collective cell movement[1][2]. In cancer, Girdin expression is often upregulated and has been associated with increased tumor invasion, metastasis, cell cycle dysregulation, and, paradoxically, either increased or decreased therapeutic sensitivity depending on context[1]. Experimentally, Girdin is an attractive but complex candidate therapeutic target for anti-metastatic cancer strategies due to its central role in cell movement and survival pathways; however, no clinically approved drugs currently target Girdin directly[1][2][3].

Other names

GIVG alpha-interacting vesicle-associated proteinCCDC88AAkt-phosphorylation enhancer

In principle, inhibitors would affect cell migration, cytoskeletal reorganization, and potentially tumor cell resistance to therapy by modulating Girdin's role in actin remodeling and signal transduction[1][2].